Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...

Elevidys offers a one-shot therapy for the disease, with a price tag of $3.2 million, whereas other drugs to treat DMD, including Sarepta’s own exon-skipping range for patients with specific ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a price target of $195.00. With a market capitalization of $11.27 billion, ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

Notably, Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s FDA-approved gene therapy, ELEVIDYS, supports the company’s significant moat, placing the company in a leadership position in muscle ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Sarepta’s net product revenue does not include collaboration, contract manufacturing or royalty revenue. Fourth quarter and full-year 2024 net product revenue for ELEVIDYS totaled $384.2 million ...